Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNR-051 in Advanced Solid Malignancies
NCT04544748Phase 1Completed
- Sponsor
- Generium
- Start
- Jul 2020
- Primary completion
- Nov 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of gnr-051 in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and melanoma (5 cohorts), sponsored by Generium. Primary endpoints: Maximum Tolerated Dose at 28 days, Dose-Limiting Toxicity at 28 days and 1 more. Started Jul 2020; status: completed.
02
Drugs
gnr-051
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)melanoma
Beyond the preview
Go deeper on NCT04544748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04544748.